Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Dow
Medtronic
Express Scripts
Baxter

Last Updated: September 25, 2022

ORAVERSE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Oraverse patents expire, and what generic alternatives are available?

Oraverse is a drug marketed by Septodont Holding and is included in one NDA. There are three patents protecting this drug.

This drug has sixteen patent family members in twelve countries.

The generic ingredient in ORAVERSE is phentolamine mesylate. There are four drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the phentolamine mesylate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Oraverse

A generic version of ORAVERSE was approved as phentolamine mesylate by HIKMA on March 11th, 1998.

  Try it Free

Summary for ORAVERSE
Drug patent expirations by year for ORAVERSE
Drug Prices for ORAVERSE

See drug prices for ORAVERSE

Recent Clinical Trials for ORAVERSE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Cairo UniversityPhase 3
sara nabilPhase 3
Dalhousie UniversityPhase 4

See all ORAVERSE clinical trials

Pharmacology for ORAVERSE

US Patents and Regulatory Information for ORAVERSE

ORAVERSE is protected by three US patents.

Patents protecting ORAVERSE

Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD OF REVERSING SOFT-TISSUE ANESTHESIA I.E. ANESTHESIA OF THE LIP AND TONGUE, AND THE ASSOCIATED FUNCTIONAL DEFICITS RESULTING FROM AN INTRAORAL SUBMUCOSAL INJECTION OF A LOCAL ANESTHETIC

Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Septodont Holding ORAVERSE phentolamine mesylate INJECTABLE;INJECTION 022159-001 May 9, 2008 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Septodont Holding ORAVERSE phentolamine mesylate INJECTABLE;INJECTION 022159-001 May 9, 2008 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Septodont Holding ORAVERSE phentolamine mesylate INJECTABLE;INJECTION 022159-001 May 9, 2008 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ORAVERSE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Septodont Holding ORAVERSE phentolamine mesylate INJECTABLE;INJECTION 022159-001 May 9, 2008 See Plans and Pricing See Plans and Pricing
Septodont Holding ORAVERSE phentolamine mesylate INJECTABLE;INJECTION 022159-001 May 9, 2008 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for ORAVERSE

See the table below for patents covering ORAVERSE around the world.

Country Patent Number Title Estimated Expiration
Hong Kong 1079444 穩定的阿爾法腎上腺素能受體拮抗藥製劑及其用途 (STABILIZED FORMULATIONS OF ALPHA ADRENERGIC RECEPTOR ANTAGONISTS AND USES THEREOF) See Plans and Pricing
South Africa 200410093 Stabilized formulations of alpha adrenergic receptor antagonists and uses thereof See Plans and Pricing
World Intellectual Property Organization (WIPO) 0185171 See Plans and Pricing
South Africa 200209811 Local anesthetic methods and kits. See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
McKesson
AstraZeneca
Baxter
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.